Marks Group Wealth Management Inc Buys 259 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Marks Group Wealth Management Inc raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 30,807 shares of the medical research company’s stock after buying an additional 259 shares during the quarter. Marks Group Wealth Management Inc’s holdings in IQVIA were worth $7,128,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in IQV. AMF Tjanstepension AB bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $148,096,000. Eagle Asset Management Inc. bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $102,982,000. iA Global Asset Management Inc. grew its position in shares of IQVIA by 1,225.3% in the 3rd quarter. iA Global Asset Management Inc. now owns 320,271 shares of the medical research company’s stock worth $63,013,000 after buying an additional 296,105 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of IQVIA by 2,765.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 271,316 shares of the medical research company’s stock worth $53,381,000 after buying an additional 261,848 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of IQVIA by 33.4% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,039,436 shares of the medical research company’s stock valued at $240,505,000 after purchasing an additional 260,271 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock valued at $10,331,003 over the last 90 days. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Up 3.2 %

IQV stock opened at $238.74 on Wednesday. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The business has a fifty day moving average price of $245.55 and a 200-day moving average price of $222.56. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The stock has a market capitalization of $43.33 billion, a P/E ratio of 32.75, a P/E/G ratio of 2.24 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter in the previous year, the business earned $2.54 earnings per share. The company’s revenue was up 3.5% on a year-over-year basis. Equities analysts forecast that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. BTIG Research assumed coverage on IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price for the company. Evercore ISI raised their target price on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research note on Thursday, February 15th. Barclays lifted their price objective on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Truist Financial lifted their price objective on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $256.80.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.